Overview

Flutiform® Compared With Seretide® in the Treatment of COPD

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether flutiform® is effective and safe in the treatment of chronic obstructive pulmonary disease (COPD).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Mundipharma Research Limited

Treatments:

Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Fluticasone-Salmeterol Drug Combination